Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study

The combination of atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) and inhibits the interaction between PD-L1 and its receptors, and tazemetostat, an EZH2 inhibitor, may lead to selective epigenetic reprogramming, alter the tumor microenvironment, and provide addit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-07, Vol.22 (7), p.504-512
Hauptverfasser:	Palomba, Maria Lia, Cartron, Guillaume, Popplewell, Leslie, Ribrag, Vincent, Westin, Jason, Huw, Ling-Yuh, Agarwal, Shefali, Shivhare, Mahesh, Hong, Wan-Jen, Raval, Aparna, Chang, Alice C., Penuel, Elicia, Morschhauser, Franck
Format:	Artikel
Sprache:	eng
Schlagworte:	Diffuse large B-cell lymphoma Epigenetic EZH2 inhibitor Immunotherapy Life Sciences Non-Hodgkin's lymphoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!